Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
Abstract Background A competitive market for off-patent biologicals leads to more affordable and high-quality healthcare. In recent years, Belgium has been characterized by its low use of biosimilars and by its shifts from off-patent biologicals toward new alternative therapies. Yet, the prescribing...
Saved in:
Main Authors: | Yannick Vandenplas (Author), Steven Simoens (Author), Philippe Van Wilder (Author), Arnold G. Vulto (Author), Florian Turk (Author), Isabelle Huys (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
by: Yannick Vandenplas, et al.
Published: (2021) -
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
by: Yannick Vandenplas, et al.
Published: (2023) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022) -
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices
by: Liese Barbier, et al.
Published: (2021) -
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
by: Yannick Vandenplas, et al.
Published: (2021)